Navigation Links
U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
Date:9/5/2012

RARITAN, N.J., Sept. 5, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.

The FDA grants priority review to medicines that may offer major advances in care or provide a treatment option where no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA will aim to complete its review within six months of the NDA submission. The NDA was submitted June 29.

"There is a growing public health need for new treatment options for multi-drug resistant tuberculosis. If approved, bedaquiline would offer the first in a new class of anti-tuberculosis drugs for patients suffering from this serious and deadly disease," said Wim Parys, M.D., Head of the Infectious Diseases therapeutic area at Janssen. "We are working closely with the FDA and other regulatory agencies in high-burden countries to quickly bring bedaquiline to the patients who need it."  

The regulatory submission was supported by 24-week data from the Phase II clinical development program, which includes an open-label study and a controlled, randomized trial that evaluated the safety and efficacy of bedaquiline versus placebo in the treatment of patients with pulmonary MDR-TB in combination with a background regimen.

Bedaquiline is a diarylquinoline discovered by scientists at Janssen.

About Janssen Research & Development, LLC
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
10. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
11. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC PACK" ... yen or $5,000 (without tax /including two pairs of JINS ... a dedicated solution of "JINS MEME" to academic researchers, and ... generated by electrooculography and six-axis sensors without API. (*Physiological data ...
(Date:11/26/2014)... SAN DIEGO , Nov. 26, 2014  Aethlon ... into a definitive agreement to raise approximately $3.3 million ... is being made by one institutional healthcare focused investor. Each ... one-fifth of a common share purchase warrant. Each whole ... at a price of $0.30 for a period of ...
(Date:11/26/2014)... Nov. 26, 2014  Genomic Health, Inc. (Nasdaq: ... Chairman, Chief Executive Officer and President, will participate in ... at The New York Palace Hotel in ... 11:30 am Eastern Time (ET). To access ... call, go to the  Investor Relations  section of the ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3
... 4, 2010 /PRNewswire / -- Streamline Health ... provider of document workflow solutions for hospitals, today announced ... delivery systems in the United States, will implement Streamline ... The solution provides an automated ...
... Syringe Locking-Device Technology at HealthAchieve Conference -- JERUSALEM, November 4, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
Cached Medicine Technology:Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 2Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 3Texas-Based Hospital Expands Utilization of Streamline Health Document Workflow Solutions 4Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 2Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 3Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 4Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 5Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 6Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 7Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference 8
(Date:11/27/2014)... 27, 2014 An inventor from Buffalo, ... fact of life, and she wants to lessen its ... later, I decided that there needed to be a ... , Easy to use and producible in design variations, ... woman’s private areas throughout the day. It avoids bad ...
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, ... be safe and produces an immune system response that could ... trial results reported by the U.S. National Institutes of Health. ... the vaccine paves the way for field-testing it in the ... early as January, said Dr. Anthony Fauci, director of the ...
(Date:11/27/2014)... Las Vegas, NV (PRWEB) November 27, 2014 ... Holiday 2014 shopping season has officially launched, Emassagechair.com ... Friday and Cyber Monday Discount Event. , Negotiating ... close relationships with top massage chair brands, Emassagechair.com has ... of their best deals and biggest discounts yet. , ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “LAB.C” was ... which features the latest and coolest technology products available to ... conducted the product review and shared with viewers ... for iOS and Android devices. , Consumers love portability and ... Their Cable Case for the iPhone5 and 5S has ...
(Date:11/27/2014)... Philadelphia, PA (PRWEB) November 27, 2014 ... alongside volunteer Aria Health employees, prepared and donated ... to the Lutheran Settlement House , a non-profit, ... and families living in Philadelphia. The dinners were ... Settlement House Senior Center, and distributed to vulnerable ...
Breaking Medicine News(10 mins):Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2
... News) -- New research points to two gene-based methods ... cancers will experience a tumor recurrence. The studies, ... to be presented Wednesday at the 2011 San Antonio ... genetic data gleaned from tumors might help doctors tailor ...
... Medical Center in Cleveland, Ohio is among 65 hospitals ... leader in quality patient care by The Leapfrog Group. ... most competitive national hospital quality award in the country, ... preventing medical errors, reducing mortality for high-risk procedures like ...
... (HealthDay News) -- U.S. officials on Tuesday said that they ... HCG weight loss products from the market. HCG stands ... placenta and found in the urine of pregnant women. The ... diet -- as low as 500 calories per day -- ...
... and commitment to patient-centered medical technology, the University ... have announced the commercial availability of a new ... to diagnose patients with high clarity images at ... an advanced form of spiral x-ray technology that ...
... Ore. The first federally funded report to compare children ... percent to 19 percent of children in the United States ... inadequate to cover the greater scope of care they require ... Care Needs in Context: A Portrait of States and the ...
... , TUESDAY, Dec. 6 (HealthDay News) -- Bed bugs appear ... only ups their "yuck" factor but also enhances the tiny ... from North Carolina State University did a genetic analysis of ... and New Jersey. Their analysis showed the bugs had low ...
Cached Medicine News:Health News:New Tests Might Better Predict Breast Cancer's Return 2Health News:New Tests Might Better Predict Breast Cancer's Return 3Health News:New Tests Might Better Predict Breast Cancer's Return 4Health News:University Hospitals Case Medical Center recognized as national leader by the Leapfrog Group 2Health News:FDA Targets Homeopathic Weight Loss Products 2Health News:FDA Targets Homeopathic Weight Loss Products 3Health News:FDA Targets Homeopathic Weight Loss Products 4Health News:Notre Dame, Purdue and GE Healthcare partner on new CT technology 2Health News:Notre Dame, Purdue and GE Healthcare partner on new CT technology 3Health News:Health care, home, school differ for children with special health care needs 2Health News:Bed Bugs Can Bypass Pitfalls of Inbreeding, Studies Say 2Health News:Bed Bugs Can Bypass Pitfalls of Inbreeding, Studies Say 3
... Hycor Biomedical Ltd Autostat™II Rheumatoid Factor IgM ... Rheumatoid Factor IgM (RF IgM). Enzyme-linked immunosorbent ... specific IgM Rheumatoid Factor in human serum. ... can be used as an aid in ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... Scheimpflug Analyzer is a high precision optical ... analysis of the anterior eye segment, based ... and a Placido Disk. , GALILEI combines ... furnishes high accuracy curvature data, while Scheimpflug ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: